Target cell

Results: 259



#Item
161Award ID: RP130276 Project Title: The mTOR-dependent nuclear transport in cancer Award Mechanism: Individual Investigator

Award ID: RP130276 Project Title: The mTOR-dependent nuclear transport in cancer Award Mechanism: Individual Investigator

Add to Reading List

Source URL: www.cprit.state.tx.us

Language: English - Date: 2014-11-20 01:49:18
162OUTLOOK SICKLE-CELL DISEASE E P IDE M IO LO GY A moving target Migration has led to an increase in the occurrence of sickle-cell disease in countries with previously low incidence of the disorder.

OUTLOOK SICKLE-CELL DISEASE E P IDE M IO LO GY A moving target Migration has led to an increase in the occurrence of sickle-cell disease in countries with previously low incidence of the disorder.

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2014-11-12 12:54:14
163Keck School of Medicine of USC Research Seminar Series “The UVRAG interactome – autophagy and beyond” Chengyu Liang, MD, PhD Assistant Professor Molecular Microbiology and Immunology

Keck School of Medicine of USC Research Seminar Series “The UVRAG interactome – autophagy and beyond” Chengyu Liang, MD, PhD Assistant Professor Molecular Microbiology and Immunology

Add to Reading List

Source URL: cafe.usc.edu

Language: English - Date: 2014-11-11 19:17:31
164Birt-Hogg-Dubé Newsletter December 2013 Vol.12, No.4  You are receiving this email because you have expressed an interest in BHD. We hope you will enjoy this and

Birt-Hogg-Dubé Newsletter December 2013 Vol.12, No.4 You are receiving this email because you have expressed an interest in BHD. We hope you will enjoy this and

Add to Reading List

Source URL: www.bhdsyndrome.org

Language: English - Date: 2013-12-20 11:02:16
165bs_bs_banner  Pathology International 2013; 63: 45–55 doi:[removed]pin.12028

bs_bs_banner Pathology International 2013; 63: 45–55 doi:[removed]pin.12028

Add to Reading List

Source URL: www.bhdsyndrome.org

Language: English - Date: 2013-01-31 06:44:37
166DOE Fuel Cell Technologies Office Record 14013: Early Market Hydrogen Cost Target Calculation

DOE Fuel Cell Technologies Office Record 14013: Early Market Hydrogen Cost Target Calculation

Add to Reading List

Source URL: hydrogen.energy.gov

Language: English - Date: 2014-11-07 16:48:27
167Birt-Hogg-Dubé Newsletter June 2014 Vol.13, No.2  You are receiving this email because you have expressed an interest in BHD. We hope you will enjoy this and

Birt-Hogg-Dubé Newsletter June 2014 Vol.13, No.2 You are receiving this email because you have expressed an interest in BHD. We hope you will enjoy this and

Add to Reading List

Source URL: www.bhdsyndrome.org

Language: English - Date: 2014-06-30 13:19:48
168Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Albert-Ludwigs-Universität Freiburg Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate

Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Albert-Ludwigs-Universität Freiburg Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate

Add to Reading List

Source URL: www.zft.uni-freiburg.de

Language: English - Date: 2011-06-06 07:53:00
169IBMCB Seminar[removed]: Evangelos Koustas Autophagy in cancer progression and therapeutic response: The role of RAS pathway and the discovery of novel PIK3CA inhibitors Autophagy is a process of self- cannibalization of

IBMCB Seminar[removed]: Evangelos Koustas Autophagy in cancer progression and therapeutic response: The role of RAS pathway and the discovery of novel PIK3CA inhibitors Autophagy is a process of self- cannibalization of

Add to Reading List

Source URL: www.eie.gr

Language: English - Date: 2014-07-08 06:51:42
170Protocol I199911: A PHASE I CLINICAL TRIAL OF mTOR INHIBITION WITH SIROLIMUS FOR ENHANCING ALVAC(2)-NY-ESO1(M)/TRICOM VACCINE INDUCED ANTI-TUMOR IMMUNITY IN OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER Kunle Odu

Protocol I199911: A PHASE I CLINICAL TRIAL OF mTOR INHIBITION WITH SIROLIMUS FOR ENHANCING ALVAC(2)-NY-ESO1(M)/TRICOM VACCINE INDUCED ANTI-TUMOR IMMUNITY IN OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER Kunle Odu

Add to Reading List

Source URL: osp.od.nih.gov

Language: English - Date: 2013-12-31 11:43:35